Exact-match domains in billion-dollar B2B categories are extraordinarily rare. This is one of the last great ones available in biotech.
There is a fundamental difference between a coined brand name and an exact-match domain. Coined names — Genentech, Illumina, Moderna — require years and tens of millions of dollars in marketing investment before they carry meaning. Exact-match names arrive pre-loaded with authority.
CrisprPharmaceuticals.com is the most direct possible statement of what a CRISPR drug company does. It requires no explanation, no translation, no brand education. A physician reading it understands immediately. An investor reads it and knows the category. A regulator sees it and grasps the mission.
In a sector where institutional credibility is existential — where companies must earn the trust of the FDA, EMA, major academic medical centers, and sophisticated biotech investors — arriving with the category's definitive domain name is a significant strategic advantage.
The 2020 Nobel Prize in Chemistry awarded to Jennifer Doudna and Emmanuelle Charpentier transformed CRISPR from a scientific acronym into global cultural vocabulary. It was front-page news in every major publication worldwide. The word CRISPR now carries instant recognition across scientific, investor, patient, and general audiences alike.
This is extraordinarily valuable for a domain. Most category-defining words in pharma require decades of industry development before they achieve this level of recognition — DNA, PCR, mRNA are examples. CRISPR achieved it in a decade and has now become the dominant framework for discussing genetic medicine.
Despite the proliferation of new TLDs, .com remains unambiguous in institutional settings. When a biotech company presents to the FDA, files an IND, submits to a major journal, or pitches at JPMorgan Healthcare Conference, their .com domain is the default expectation. Alternative extensions introduce unnecessary friction at precisely the moments when first impressions matter most.
CrisprPharmaceuticals.com is the .com — the only one. Every other variation is a fallback.
| Domain | CrisprPharmaceuticals.com |
| Characters | 26 (optimal for category) |
| Extension | .COM |
| Type | Exact-Match Descriptive |
| Words | 2 (CRISPR + Pharmaceuticals) |
| Trademark conflicts | Clean — descriptive terms |
| Search authority | Exceptional (EMD advantage) |
| Global readability | Universal — English scientific standard |
| Investor recognition | Immediate |
| Regulatory clarity | Unambiguous |
"The domain is the first line of your brand's biography. CrisprPharmaceuticals.com tells the whole story before a single page loads."
— Domain brand strategy perspectiveExact-match domains in competitive B2B categories receive a measurable boost in organic search rankings — particularly in queries where commercial intent aligns with the domain name. "CRISPR pharmaceuticals" is searched thousands of times monthly by investors, clinicians, journalists, and patients. The company that owns this domain owns that organic territory.
The company that acquires CrisprPharmaceuticals.com will own the most authoritative online address in gene editing therapeutics.
Begin Acquisition